2021-12-09
Avistone Completes $200 Million-plus Fundraising, with Vivo Capital as the Lead Investor
On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") announced the closure of Series A funding, raising over $200 million.
View details >
2022-09-28
Acceptance of Avistone's application for launch of MET inhibitor Vebreltinib enteric capsule (PLB-1001) in China
Avistone recently announced the application by its subsidiary Purun'ao Biotechnology for the launch of its Vebreltinib enteric capsule. The application has been accepted on September 24 by the National Medical Products Administration for priority review. The proposed application of Vebreltinib is for the treatment of partial late-stage or metastatic NSCLC patient with Mesenchymal-epithelial transition factor (MET) Exon 14 skipping.
View details >
2021-12-09
Primavera Invests in Innovative Drug Company Avistone | Primavera Headlines
On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone"), a company focusing on the research of targeted drug for precision treatment announced closure of Series A funding, raising over $200 million from Primavera, Vivo Capital and Bain Capital.
View details >
2022-03-15
Bain Headline | Bain Capital Invests in Innovative Drug Company Avistone Pharmaceuticals to Help It Build Cancer Precision Treatment Platform
Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") recently announced closure of Series A funding, raising over $200 million.
View details >
Company Profile
©2022 Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd.
京ICP备2020040683号-2